Haematologisch Onkologische Praxis Eppendorf / Norddeutsches Studienzentrum für Innovative Onkologie

The Haematologisch Onkologische Praxis Eppendorf focuses on Neoplasms, specifically advanced breast cancer. Current studies aim to evaluate a new oral selective estrogen receptor degrader compared with standard hormonal therapy to improve progression‑free survival.

• Comparison of ARV‑471 versus fulvestrant in ER(+)/HER2(‑) disease
• Assessment of efficacy in patients with prior endocrine treatment

This work supports the development of more effective targeted options for patients whose disease has progressed after standard endocrine therapy.

Research at the site also addresses gastroesophageal adenocarcinomas, including gastric, gastroesophageal junction, and esophageal subtypes. Trials are designed to compare a novel agent with the physician’s choice of therapy to determine overall survival benefits.

• Evaluation of MK‑2870 against standard care in metastatic gastric/GEJ/esophageal cancer
• Focus on overall survival as the primary endpoint

These investigations aim to expand treatment options for patients with advanced gastrointestinal tumors, a population with limited effective therapies.